July 25 (Reuters) - Roche on Thursday raised its

full-year earnings guidance, driven by high demand for newer

drugs such as eye medicine Vabysmo.

Core earnings per share are targeted to grow in the "high

single digit range", excluding the effect of currency swings and

the resolution of tax disputes in 2023, it said in a statement.

It had previously predicted a "mid single-digit" percentage

growth rate.